Recent studies have reported higher rates of hepatocellular carcinoma (HCC) in individuals treated with direct-acting antivirals (DAAs). However, making definitive conclusions has been challenging because of the heterogeneous populations and methodologies of these reports. We investigated whether DAA use is associated with higher rates of incident HCC compared to treatment with interferon (IFN)-based regimens. We performed a retrospective, population-based cohort study using the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) database. In a cohort of 17,836 persons, sustained virological response (SVR) was achieved by 66.6% and 96.2% of the IFN and DAA groups, respectively. Among all treated persons, risk of HCC was not higher in the DAA group compared to the IFN group (hazard ratio, 1.07; 95% confidence interval, 0.55, 2.08). Among persons with cirrhosis who achieved SVR, neither the HCC incidence rate nor HCC-free survival were significantly different in the DAA group compared to the IFN group (21.2 vs. 22.8 per 1,000 person-years; P 5 0.78 and log-rank P 5 0.17, respectively). Untreated persons with cirrhosis had a significantly higher HCC incidence rate (45.3 per 1,000 person-years) compared to those treated with either IFN or DAAs (P 5 0.03). Both groups of treated persons had significantly lower probability of HCC development compared to untreated persons (log-rank, P 5 0.0004). Conclusion: DAA treatment is not associated with a higher risk of HCC in persons with cirrhosis with chronic HCV infection in the short term. Previously reported higher rates of HCC associated with DAA treatment may be explained by both the presence of relatively fewer baseline HCC risk factors in persons treated with IFN as well as selection bias, given that DAA regimens were used to treat persons at higher risk for developing HCC. (HEPATOLOGY 2018;67:2244-2253).
H epatocellular carcinoma (HCC) is the second-leading cause and fastest rising cause of cancer-related death worldwide.
(1) One of the most common risk factors for HCC is cirrhosis attributed to chronic infection with the hepatitis C virus (HCV), which is estimated to infect over 150 million people globally. (2, 3) For decades, the standard of care for HCV treatment had been interferon (IFN)-based regimens, with approximately 50%-60% of eligible patients achieving sustained virological response (SVR). IFN-induced SVR has been shown to result in an approximately 4-fold reduction of HCC risk regardless of stage of liver disease. (4, 5) Thus, with the recent development of highly efficacious direct-acting Abbreviations: AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; cDDD, cumulative defined daily dose; CI, confidence interval; DAA, direct-acting antiviral; DCL, daclatasvir; ERCHIVES, Electronically Retrieved Cohort of HCV Infected Veterans; FDA, U.S. Food and Drug Administration; FIB-4, Fibrosis-4; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HR, hazard ratio; ICD, International Classification of Diseases; IFN, interferon-based regimen; LDV, ledipasvir; PEG, pegylated interferon; PPI, proton pump inhibitor; PRoD, paritaprevir/ritonavir/ombitasvir 1 dasabuvir; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir; SVR, sustained virological response; SVR12, SVR at 12 or more weeks posttreatment; VA, Veterans Affairs. antiviral (DAA) agents against chronic HCV, in whom >90% of treated patients achieved SVR, expectations were that the use of DAAs would result in significantly lower rates of HCC in these patients. (6, 7) However, several recent studies reported a paradoxically increased risk of HCC in patients treated with DAA therapy, particularly among those with previously treated HCC, whereas others have not supported this observation. (8) (9) (10) (11) (12) (13) (14) Moreover, given that the studies were performed in relatively small, heterogenous populations, and had inconsistent methodologies, definitive conclusions based on these studies is challenging.
Thus, we sought to investigate whether DAA treatment is associated with higher rates of incident HCC using a large, well-established national cohort of HCV-infected U.S. veterans without a past diagnosis of HCC.
Patients and Methods

STUDY DESIGN AND DATA SOURCE
We conducted a retrospective cohort study among HCV-infected persons in the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) database. ERCHIVES is a large, well-established national cohort of HCV-infected and uninfected Veterans and has been described. (15) (16) (17) (18) All HCV-infected Veterans at any of the nation-wide Department of Veterans Affairs (VA) medical facilities with a positive HCV antibody test between 2002 and 2016 were identified. Demographic, clinical, and laboratory data were obtained from the National Patient Care Database and the Corporate Data Warehouse, and pharmacy information, including all prescriptions written, doses, duration, number of pills, number of refills, and date of refills, was retrieved from the Pharmacy Benefits Management database. Data were then merged based on established algorithms. The study was approved by the Institutional Review Board at the VA Pittsburgh Healthcare System.
STUDY PARTICIPANTS
Persons were included in the study cohort if they had positive serology for HCV antibody and were excluded if they had coinfection with human immunodeficiency virus (HIV), a positive test for hepatitis B surface antigen (HBsAg) or a diagnosis of hepatocellular carcinoma prior to baseline (defined below).
Furthermore, persons were excluded if prior to baseline they: 1) were missing an HCV RNA or Fibrosis-4 (FIB-4) score, 2) did not have complete data to permit calculation of a repeat FIB-4 score at least 12 weeks after baseline, or 3) were missing HCV-RNA data to determine attainment of SVR at 12 or more weeks posttreatment (SVR12). This cohort was then divided into the following groups based on treatment received: Group A (IFN): Persons included if received treatment with pegylated interferon (PEG) and ribavirin (RBV) for 28 days. If the person received multiple courses of PEG1RBV, the first treatment course was used for establishing baseline. Persons treated with standard IFN were excluded from this study. Group B (DAA): Persons included if received treatment with one of the following regimens: sofosbuvir 1 simeprevir 6 RBV (SOF/SMV); sofosbuvir 1 ledipasvir 6 RBV (SOF/LDV); sofosbuvir 1 daclatasvir 6 RBV (SOF/DCL); or paritaprevir/ritonavir/ombitasvir 1 dasabuvir 6 RBV (PRoD) for 28 days. Other, newer DAA regimens were not included because small numbers of persons initiated those regimens. Group C: Persons who never received any HCV treatment for 28 days.
DEFINITIONS
For persons in the treatment group, baseline was the date of HCV treatment initiation. For the untreated group, we assigned the baseline to equal the duration of HCV infection before treatment initiation in the corresponding treated person. This was calculated by determining the average time between the first HCV antibody-positive date and treatment initiation date for the treated persons group, and adding the same duration to the time between the first HCV antibodypositive date in each untreated person and assigning that date as the baseline. Treatment completion was defined according to U.S. Food and Drug Administration (FDA)-approved labels for each drug regimen.
Cirrhosis was defined as a FIB-4 score of >3.5, based on published work (16) Persons were defined as having diabetes using a combination of blood glucose measurement, use of anti-diabetic agents, and International Classification of Diseases (ICD)-9 codes, as previously described. (19) Mean ALT, AST, and gamma glutamyl transferase were defined as the average of two values closest to and before baseline. Alpha-fetoprotein (AFP) level was defined as the most recent available value but preceding the first diagnosis of HCC. History of alcohol/ drug abuse or dependence was based on the presence of at least one inpatient or two outpatient ICD-9 diagnoses any time from 12 months before to 3 months after baseline. For diabetes, alcohol and drug abuse, and other independent variables, ICD-10 codes were used for data after October 1, 2015.
Drug exposure to proton pump inhibitors (PPIs) and statins was defined as >30 cumulative defined daily doses (cDDDs) prescribed during the study period. The use of cDDD is recommended by the World Health Organization and is used widely for comparison of drug exposure. Briefly, information regarding the dates of prescriptions ordered, number of days prescribed, number of pills per prescription, and number of refills ordered were collected. Using this information, the cDDD of PPIs and statins was calculated for each subject as described previously. (19) PRIMARY OUTCOME Our primary outcome of interest was the development of incident HCC, defined as the presence of at least one inpatient or two outpatient ICD-9 or ICD-10 codes for HCC made 3 months after baseline. This approach has been recently validated within VA data compared to medical record review. (20) Time to development of HCC was determined relative from baseline (i.e., treatment initiation). Given that advanced fibrosis is one of the strongest predictors of HCC development, we performed our primary analysis on persons in our cohort with baseline cirrhosis (FIB-4 >3.5).
STATISTICAL ANALYSIS
Baseline demographic and clinical factors were compared between the DAA, IFN, and untreated groups using chi-square tests for categorical variables and Wilcoxon rank-sum or t tests, as appropriate, for continuous variables. We calculated the unadjusted incidence rate of HCC per 1,000 person-years for all three treatment groups. Kaplan-Meier curves were generated to demonstrate time to development of HCC by SVR status for each treatment regimen, stratified by the presence of HCC risk factors at baseline, including cirrhosis.
For our primary analysis, we performed incidence rate calculations and Cox regression among persons with baseline cirrhosis (FIB-4 >3.5) to examine the risk of HCC in the DAA group compared to the IFN group. In a secondary analysis, all treated persons were included, regardless of FIB-4 score. We also performed a sensitivity analysis in which we performed incidence rate calculations after only including those with FIB-4 scores that were calculated from values collected with 12 months of baseline.
We performed an additional secondary analysis using multivariable Cox regression analysis to identify factors that were independently associated with HCC. We also performed a sensitivity analysis in which we performed Kaplan-Meier analysis to assess the probability of HCC development in individuals with specific risk factors for HCC, including age and baseline AFP levels. SAS (version 9.4; SAS Institute Inc., Cary, NC) and STATA software (version 11; StataCorp LP, College Station, TX) were used for statistical analyses.
Results
BASELINE CHARACTERISTICS
From the ERCHIVES database, we identified 17,836 persons that met criteria for inclusion in this study (Fig. 1) . We divided this cohort into three groups based on treatment exposure. A comparison of the baseline demographics and clinical characteristics of these populations is shown in Table 1 . Overall, all three groups were predominantly male and had clinically similar median HCV-RNA levels and body mass index (BMI). Notably, DAA-treated persons were significantly older (62 vs. 54 years; P < 0.01) and more commonly had cirrhosis (19.9% vs. 13.1%; P < 0.01) compared to persons treated with IFN. In addition, DAA-treated and untreated persons more frequently had diabetes, higher median AFP levels, and higher PPI and statin use compared to IFN-treated persons. SVR was attained in 66.6% and 96.2% of persons in the IFN and DAA groups, respectively. Mean followup time was 2,719.2 days for IFN-treated persons and 396.4 days for DAA-treated persons. There were 196 incident HCC events among the IFN-treated persons and 50 incident HCC events among the DAA-treated persons (Table 1) .
EFFECT OF TREATMENT REGIMEN ON INCIDENT HCC
To help account for the effect of baseline HCC risk factors (i.e., cirrhosis) in the risk of HCC development in both treated populations, we performed our primary analysis on persons with cirrhosis. For persons with cirrhosis who achieved SVR, we found no significant difference in HCC incidence rate between the DAAand IFN-treated groups (22.8 vs. 21.2 per 1,000 person-years; P 5 0.78; Table 2 ). In contrast, untreated persons with cirrhosis had a significantly higher HCC incidence rate than either of the two treatment groups (45.31 per 1,000 person-years; P 5 0.03). Among persons with cirrhosis who did not achieve SVR, the incidence of HCC was higher than those who did achieve SVR, although there was no significant difference between the rates in the DAA-and IFN-treated groups (62.81 vs. 48.90 per 1,000 personyears; P 5 0.59).
We next performed Kaplan-Meier analyses to determine the probability of HCC development in persons with cirrhosis who achieved SVR in each of the treatment groups. Persons with cirrhosis who achieved SVR with either DAA-or IFN-based therapy had lower probability of developing HCC compared to the untreated group (log-rank, P 5 0.0004; Fig. 2) .
We also performed a secondary analysis in which we assessed HCC incidence in the entire cohort, which included persons without cirrhosis. Interestingly, among all persons who achieved SVR, the DAAtreated group had a significantly higher HCC incidence rate compared to the IFN-treated group (7.41 vs. 3.48 per 1,000 person-years; P < 0.01; Supporting Table S1 ). However, among individuals who did not achieve SVR, the HCC incidence rates between the two groups were not significantly different (P 5 0.44).
We next performed a sensitivity analysis in which we calculated HCC incidence rates after limiting our definition of baseline FIB-4 to within 12 months before baseline. Overall, 1,933 values for FIB-4 were excluded in this sensitivity analysis to meet this criterion (209 from the IFN group, 82 from the DAA group, and 1,642 from the untreated group). Overall, 13.3% of IFN-treated persons were classified as with cirrhosis compared to 20% of DAA-treated persons, similar to what was observed in our primary cohort (Supporting Table  S2 ). Among those included in the sensitivity group, there were 183 incident cases of HCC in IFN-treated persons and 48 incident cases among DAA-treated persons. We also limited our definition of baseline AFP to only those values collected within 12 months before baseline. A significant number of persons (n 5 14,960) in our cohort did not have an AFP within 12 months before baseline, but baseline AFP after these exclusions among the three groups was also quite similar to our primary cohort.
In this sensitivity analysis, DAA treatment was associated with a significantly lower incidence rate of HCC compared to IFN treatment (17.90 vs. 31.99 per 1,000 person-years; P < 0.01) among all persons with cirrhosis. This apparent difference by treatment group disappears, however, when comparing only persons with cirrhosis who achieved SVR (16.76 vs. 19.77 per 1,000 person-years, respectively; P 5 0.51; Supporting Table S3 ). Furthermore, persons with cirrhosis who did not achieve SVR had a higher incidence of HCC than those who did achieve SVR, regardless of which type of therapy they failed. This was significant for persons treated with IFN (46.65 vs. 19.77 per 1,000 person-years), but not quite significant for DAAs (38.03 vs. 16.76 per 1,000 personyears), likely because of the very small number of DAA-treated persons who did not achieve SVR. Similar to treated persons who did not achieve SVR, persons with cirrhosis who did not receive any treatment had a higher HCC incidence rate compared to either of the two treatment groups.
EFFECT OF DAA TREATMENT REGIMENS ON INCIDENT HCC
We next performed a separate subgroup analysis investigating the incidence of HCC in persons treated with specific IFN-free DAA treatment regimens. These included an early DAA regimen, SOF/SMV, and the more recently approved SOF/LDV. SOF/ DCL was not included because of low patient numbers, and PRoD was not included because of insufficient follow-up time. The baseline characteristics for this subgroup are shown in Supporting Table S4 . Persons treated with SOF/SMV had significantly higher baseline rates of cirrhosis (39.6%) compared to those treated with IFN (13.1%; P < 0.01) and SOF/LDV (18.9%; P < 0.01).
Among persons with cirrhosis who achieved SVR, there was a trend toward a higher HCC rate in the SOF/ SMV group compared to the SOF/LDV group (33.26 vs. 15.49 per 1,000 person-years; P 5 0.07; Table 3 ) and a weaker trend toward a higher HCC rate in the SOF/ SMV group compared to the IFN group (33.26 vs. 21.20 per 1,000 person-years; P 5 0.18). Consistent with these analyses, Kaplan-Meier analysis revealed that SVR after SOF/SMV may be associated with higher probability of HCC development compared to SVR after SOF/LDV and or IFN (Supporting Fig. S1 ).
These results were robust to a sensitivity analysis with a more restrictive definition of baseline FIB-4 as described before (Supporting Table S5 ).
RISK FACTORS FOR HCC DEVELOPMENT
We also identified risk factors for the development of HCC using a multivariate Cox proportional hazards (16) and PPI use was associated with a higher risk of HCC (HR, 1.65; 95% CI, 1.07, 2.55). We also performed supplemental Kaplan-Meier analyses of HCC-free survival of other groups of DAA or IFN SVR persons at inherently higher risk of HCC, including those with older age and those with higher baseline AFP values. In each of these analyses, there was no difference in HCC-free survival between the two treatment groups (Supporting Fig. S2A,B) . Though achievement of SVR was not associated with a significantly lower HCC rate in our original analysis, when we performed a multivariable analysis of the data after limiting the Abbreviation: N/A, not applicable.
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baseline FIB-4 to within a 12-month window before baseline, SVR was statistically significant (HR 5 0.60; 95% CI, 0.38, 0.93; Supporting Table S6 ).
Discussion
The availability of highly effective DAAs has revolutionized HCV treatment and has been anticipated to further reduce the incidence of HCC given extremely high rates of SVR. However, recent conflicting data regarding whether the risk of HCC after DAA treatment is higher has made it critically important to determine whether this is, in fact, true given the millions of patients who could potentially benefit from DAA therapies. In this study, we analyzed the association between DAA and IFN treatment and HCC incidence among individuals with chronic HCV while controlling for other clinically relevant risk factors for HCC that we believed were not sufficiently controlled for in previous analyses that suggested the HCC rate was higher after DAA treatment.
In our cohort, we found that DAA-treated persons did have a significantly higher HCC rate than IFNtreated persons (Supporting Table S1 ), but they also had a significantly higher rate of known risk factors for HCC, including cirrhosis, older age, and higher baseline AFP level. When we performed our primary analysis in persons with cirrhosis alone, we found no difference in HCC-free survival between the DAA and IFN groups. This finding strongly suggests that the pretreatment risk of HCC is what drives the posttreatment risk of HCC. Observed differences in the incidence of HCC between DAA-and IFN-treated groups are therefore very unlikely to be related to the treatment itself.
To explain the higher prevalence of underlying HCC risks among DAA-treated individuals in our cohort, we evaluated for an effect of the common practice of "warehousing" of patients, that is, awaiting curative treatment for those who could not be cured with existing (i.e., IFN) treatment, (21) (22) (23) on prevalence of HCC risk factors. We analyzed the treatment trends of our cohort using a bar plot (Supporting Fig. S3 ). This plot shows that although IFN was the primary treatment of those who entered our cohort before the FDA approval of SOF, SOF-based treatments quickly overtook IFN as the preferred treatment modality in 2014, as soon as both SOF and SMV became available in the VA system. We therefore hypothesized that treatment with the earliest DAA regimens, specifically SOF/SMV, which was used to treat those who had previously failed treatment with IFN, may function as a surrogate for greater baseline risk for HCC, therefore confounding the association between the earliest DAA regimens and HCC incidence in historical patient cohorts. We further hypothesized that the next-wave DAA regimens were used to treat patients with comparatively lesser degrees of underlying liver disease, and would therefore be associated with a lower risk of HCC compared to the first wave of DAA. Indeed, in our analysis, we found that persons treated with SOF/ SMV, the first combination DAA that was FDA approved, had higher rates of cirrhosis compared not only to IFN treated persons, but also to those treated with more recent DAA-based therapies, including SOF/LDV, which became available a year after SOF/ SMV. Furthermore, SOF/SMV-treated persons had the highest risk of HCC compared not only to IFNtreated persons, but also to those treated with SOF/ LDV. Similar to our findings, Conti et al. also found that treatment of persons with cirrhosis with the earliest DAA regimens, including SOF/RBV, was associated with higher rates of HCC (10 of 52; 19.2%) compared to those treated with the subsequently approved regimens SOF/LDV (1 of 24; 4.2%) and PRoD (2 of 52; 3.8%). (9) However, Conti et al. did not present detailed baseline characteristics for each of the DAA treatment subgroups. Similarly, several other studies that have reported a higher rate of HCC after DAA treatment have not provided baseline characteristics of subgroups treated with various DAA combinations, likely attributed to the overall small numbers in these studies. (8, (10) (11) (12) Treatment with early DAA regimens may therefore represent a novel confounding factor contributing to selection bias that has not been reported nor rigorously adjusted for in past studies. Thus, in contrast to reports in which a higher rate of HCC was found among DAA-treated persons, we clearly show that DAA treatment is not associated with a higher risk of HCC development compared to IFN treatment when controlling for differences in baseline HCC risk factors between the treatment groups.
Importantly, our results support the concept that treatment and achievement of SVR with any antiviral regimen is the most important determinant of a lower HCC risk. Among all persons with cirrhosis, untreated controls had significantly higher rates of HCC compared to both DAA-and IFN-treated groups (Table  3) . Moreover, the lower HCC risk is most likely attributable primarily to the attainment of SVR. Compared to treated persons with cirrhosis who attained SVR, lack of SVR achievement was associated with significantly higher incidence rates of HCC in IFN-treated persons (48.90 vs. 21.20 per 1,000 person-years; Table  2 ). In DAA-treated persons, there was a trend toward statistical significance (Table 2) , but the very small number of treatment failures (n 5 222; 3.8%) strongly limited the statistical power of this comparison.
The strength of our work lies in the large national cohort used along with long length of follow-up as well as serial measurements of many detailed baseline characteristics. Moreover, our adjustment for baseline risk factors for HCC (cirrhosis, Child-Pugh stage, age, diabetes mellitus, history of alcohol abuse, and baseline AFP level) was not performed in many of the studies that reported an increased risk of HCC.
Our study has a number of limitations. A key limitation of our study is the relatively short follow-up time in the DAA cohort, a result of the recent introduction of DAAs into the HCV treatment model. Future studies should be performed as the cohort of DAA-treated persons matures to ensure that our findings are durable. Our study may also be limited by its generalizability, given that our cohort was comprised of veterans who are almost all male and have higher rates of smoking and alcohol use than the general population. Our study is also limited by its design as a retrospective cohort study; however, prospective studies comparing DAA therapy with IFN would be unethical because DAAs have essentially replaced IFN in the treatment of HCV. In addition, we used a clinical score (the FIB-4 score), rather than liver biopsy, to identify persons with cirrhosis. However, the FIB-4 is a validated and widely used marker of liver fibrosis progression in chronic HCV (24) and has been frequently used in epidemiological studies as a surrogate for a diagnosis of cirrhosis. (25, 26) We also could not address the contribution of surveillance practices to the perceived elevated risk of HCC following DAA treatment because these data were not available to us. We also note that treatment assignment in this cohort was confounded by calendar time, because IFN was rarely used as a treatment after the availability of DAAs, but there is no available evidence to suggest that there is a biological interaction between calendar time and treatment regimen. Finally, we excluded persons with a past diagnosis of HCC and so could not address the question of whether there is a higher recurrence rates of HCC after treatment with DAA, which has been reported in some, (8, 10, 11) but not all studies. (13, 27, 28) We took this approach because we believe that de novo occurrence is the more clinically relevant issue, and the risk of recurrence following HCC will be higher than the de novo rate regardless of HCV treatment type.
In conclusion, in persons with cirrhosis with chronic HCV infection, we found no association between HCC incidence rates and DAA treatment compared to IFN treatment in this large, retrospective cohort study. Furthermore, our secondary analyses suggested that both insufficient controlling for baseline risks for HCC and selection bias likely drove the reported associations between DAA treatment and increased HCC risk.
